AI Weekly Malaysia

Summaries

Short AI and tech summaries with source links, signal scores, and why each update matters for builders, founders, and Malaysian tech workers.

Reset

Showing 1-2 of 2 results

DateProviderScoreSummary
17 Nov 2026, 10:50 PMTechCrunch3.0 Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs raised a $5B Series C co-led by Greenoaks and Sequoia, with Andreessen Horowitz joining and existing investors including Alphabet’s GV and CapitalG, Thrive, MGX, Temasek, and the UK Sovereign AI Fund. The DeepMind spinout says its AI drug-design engine has produced positive preclinical results in oncology and immunology, and it has deals with Eli Lilly, Novartis, and Johnson & Johnson; the round follows a $2.1B Series B in May and will fund the engine plus expansion into more medicine types. Isomorphic did not disclose a valuation, though Bloomberg reported it was seeking a $50B valuation; Demis Hassabis left the DeepMind CEO role to focus on drug discovery and became DeepMind chairman, after sharing the Nobel Prize in chemistry with John Jumper for AlphaFold.

Why: For most developers and SaaS founders, this is a biotech funding story with no direct tooling, API, or platform change to adopt; the concrete signal is that AlphaFold-derived commercial work is being capitalized at biotech scale ($5B round, reported $50B valuation target) and validated through pharma partnerships and preclinical results, not through a developer product. AI/ML learners should treat it as a long-horizon research-commercialization data point, not a reason to pivot into drug discovery, and local SaaS founders should not read it as a shift in Malaysian startup conditions.

17 Nov 2026, 9:58 PMCNBC Technology3.0 Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO

Isomorphic Labs, the AI drug-discovery startup Demis Hassabis has led since it spun out of DeepMind in 2021, raised a $5 billion Series C announced 17 Nov 2026 — roughly three and a half months after Hassabis stepped back as CEO of Google DeepMind. The round was co-led by Greenoaks and Sequoia Capital alongside Andreessen Horowitz, with Alphabet also investing, and is earmarked for designing and developing new medicines with AI. The article notes 2026 has been a record funding year for drug-discovery startups, with OpenAI and Anthropic also investing in AI-for-medicine tools.

Why: There is no technical or product change here for builders to act on: no model, API, benchmark, price, or availability was announced, only a capital raise and investor list. The one concrete signal is where late-stage AI money is landing in 2026 — a single $5B round into a wet-lab-adjacent vertical, with Alphabet investing in a company its former DeepMind CEO runs — which is context for founders deciding whether to pitch horizontal AI tooling or a regulated vertical like biotech. For a Malaysian dev or SaaS team, nothing in this text changes what you build this week.

Top